About
Cancer medicines
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (9)
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
754
By Phase
PHASE1: 3PHASE1/PHASE2: 1PHASE3: 1PHASE2: 1
By Status
RECRUITING: 2UNKNOWN: 1TERMINATED: 1SUSPENDED: 1COMPLETED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT05367388Lead Sponsor
A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants
PHASE1Unknown
48 participants
Started: May 20, 2022 · Completed: Dec 31, 2022
NCT04743505Collaborator
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
PHASE1/PHASE2Recruiting
27 participants
Started: Jan 18, 2022 · Completed: May 31, 2030
NCT05054543Lead Sponsor
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
PHASE3Terminated
140 participants
Started: Nov 17, 2021 · Completed: Aug 22, 2024
NCT05055518Lead Sponsor
APL-102 Capsule in Patients With Advanced Solid Tumors
PHASE1Suspended
30 participants
Started: Aug 2, 2021 · Completed: Dec 31, 2028
NCT04839341Lead Sponsor
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
PHASE1Completed
12 participants
Started: Feb 24, 2021 · Completed: Jun 28, 2024
Locations (1)
Headquarters
Foster City, CA, United States
Map
Loading map...